Honest Criticisms and Limitations of the Krystal Zolpidem ER Trial

At a glance

| Parameter | Detail | |-----------|--------| | N | 1,018 randomized | | Intervention | Zolpidem ER 12.5 mg nightly | | Comparator | Placebo | | Duration | 6 months (24 weeks) | | Primary endpoint | Patient-reported sleep maintenance (wake after sleep onset, WASO) | | Key result | Sustained improvement in sleep onset latency and WASO vs. placebo over 24 weeks | | Sponsor | Sanofi-Aventis |

The Enrichment Design: Who Actually Entered Randomization?

The trial used an open-label run-in period before randomization. Patients first received zolpidem ER for a defined period, and only those who tolerated and responded to the drug advanced into the double-blind phase. This is an enriched-responder withdrawal design, sometimes called "randomized withdrawal."

What this means in practice: the 1,018 patients randomized were pre-selected to be people for whom zolpidem ER already worked. Anyone who experienced intolerable side effects, next-day sedation, or no sleep benefit during run-in never made it into the efficacy dataset. The trial therefore answers the question "does zolpidem ER continue to work in people it already helped?" rather than "does zolpidem ER work for insomnia patients broadly?"

This distinction matters. The enrichment design inflates effect sizes relative to what a prescriber would see when writing a new prescription for an unselected patient. The FDA's 2005 guidance on enrichment strategies acknowledges this trade-off explicitly: enrichment improves statistical power but narrows external validity.

Exclusion Criteria That Limit Generalizability

The Krystal trial excluded patients with:

• Psychiatric comorbidities (major depression, anxiety disorders, substance use)
• Sleep apnea (AHI >15)
• Chronic pain conditions
• Use of other CNS-active medications
• Shift-work or irregular schedules
• BMI above a defined threshold in some analyses

Real-world insomnia rarely presents in isolation. The NIH State-of-the-Science Conference on insomnia reported that 40-50% of chronic insomnia patients carry a comorbid psychiatric diagnosis. By excluding these groups, the Krystal trial produced data that applies cleanly to a narrow slice of clinical practice: otherwise healthy adults with primary insomnia, no medications, no psychiatric history.

Shift workers, older adults on polypharmacy, and patients with depression-associated insomnia (a population that frequently receives zolpidem in practice) were systematically absent from the evidence base.

Subjective Endpoints and the Absence of Polysomnography

The primary outcome was patient-reported WASO collected via morning diaries. No polysomnographic (PSG) confirmation was performed during the six-month maintenance phase.

This matters because:

| Consideration | Implication | |---------------|-------------| | Subjective WASO correlates imperfectly with objective WASO | Patients on sedative-hypnotics may underestimate wakefulness due to anterograde amnesia effects | | No actigraphy validation | Total sleep time claims rest entirely on self-report | | Diary compliance over 24 weeks | Fatigue with daily reporting introduces missing data and recall bias |

Earlier zolpidem PSG studies (shorter duration) showed objective sleep improvements, but extrapolating those measurements across six months without re-confirmation introduces uncertainty. The Ambien CR prescribing information references PSG data only from short-term (2-3 week) studies, not from this six-month protocol.

Statistical Considerations

Several analytic choices deserve scrutiny:

Multiple testing. The trial assessed sleep onset latency (SOL), WASO, total sleep time (TST), sleep quality, and next-day functioning across multiple timepoints. The primary analysis plan addressed multiplicity, but secondary and exploratory endpoints were numerous. With six months of monthly assessments, the number of statistical comparisons grows quickly.

Effect size magnitude. The reported WASO difference between zolpidem ER and placebo was statistically significant but clinically modest in absolute terms. A reduction of 15-25 minutes of wakefulness per night is real, but whether patients perceive this as meaningful varies. The trial did not pre-specify a minimal clinically important difference (MCID) threshold.

Attrition. Over 24 weeks, dropout rates accumulated. The published analysis used mixed-model repeated measures (MMRM), which handles missing data under the "missing at random" assumption. If patients who dropped out did so because zolpidem stopped working (a "missing not at random" scenario), MMRM may overestimate sustained benefit.

No dose-response arm. The trial tested only 12.5 mg. Without a lower-dose comparator, there is no way to assess whether 6.25 mg (the lower available ER strength) maintains similar durability, or whether the 12.5 mg dose carries unnecessary exposure for some patients.

Industry Sponsorship and Conflict of Interest

Sanofi-Aventis funded the trial, provided the study drug, and employed several co-authors. The lead author, Andrew Krystal, had financial relationships with the sponsor disclosed in the publication.

This does not invalidate the data, but it introduces recognized bias vectors:

• Sponsor-designed trials show larger effect sizes on average than investigator-initiated studies (a finding replicated across therapeutic areas in Lexchin et al., BMJ 2003)
• Publication timing aligned with the commercial lifecycle of Ambien CR (launched 2005, patent considerations through 2010s)
• The enrichment design itself, which maximizes the probability of a positive result, was selected by the sponsor's study team

The ICMJE disclosure standards were followed, but readers should weight industry-sponsored enrichment trials differently than publicly funded pragmatic trials when making formulary or guideline decisions.

What the Trial Did Not Measure

Several clinically important outcomes were absent from the protocol:

Rebound insomnia. The trial did not include a structured discontinuation phase with post-drug sleep monitoring. When patients stopped zolpidem ER at week 24, no systematic collection of rebound data occurred. The American Academy of Sleep Medicine (AASM) guidelines note that rebound insomnia is a known risk with Z-drug withdrawal, and the absence of this data from the longest efficacy trial is a gap.

Tolerance assessment. While the trial reported sustained efficacy across six months, the enrichment design complicates interpretation. True tolerance (requiring higher doses for the same effect) cannot be evaluated when the population is pre-selected for continued response and only one dose is tested.

Next-day functional impairment. The trial collected some self-reported daytime functioning data, but did not use driving simulators, psychomotor vigilance tasks, or objective cognitive assessments. The FDA later issued a 2013 safety communication requiring lower zolpidem doses for women based on next-morning impairment data, a risk dimension this trial did not rigorously capture.

Falls and complex sleep behaviors. No systematic tracking of parasomnias, sleep-driving, or falls was built into the protocol. These events are rare per-patient but clinically serious, and a six-month exposure window in 1,018 patients would have been an opportunity to quantify incidence.

Post-Publication Commentary

The trial was published in Sleep (2010), a peer-reviewed journal with rigorous editorial standards. Formal published rebuttals or letters-to-the-editor specifically targeting this study are limited in the indexed literature. This partly reflects that the trial delivered expected results using an accepted (if conservative) design.

Indirect criticism came from several directions:

• The AASM's 2017 clinical practice guidelines rated the overall evidence for long-term hypnotic use as low quality, citing the enrichment designs and industry sponsorship of available trials as methodological concerns
• Comparative effectiveness researchers noted that no head-to-head trial compares six-month zolpidem ER against cognitive behavioral therapy for insomnia (CBT-I), the first-line recommendation
• The 2013 FDA dose reduction for women highlighted that safety signals emerged after this trial's publication, suggesting the six-month dataset was insufficient to capture the full risk profile

Placing This Trial in Context

The Krystal 2010 study remains cited because it is, quite simply, the only RCT demonstrating six-month zolpidem ER efficacy. That uniqueness is both its strength and its vulnerability. No independent replication exists. No pragmatic trial has tested whether the enrichment-design results hold in unselected populations. No study has compared six-month zolpidem ER to six-month CBT-I.

For clinicians, the honest read is: this trial proves that pre-selected responders continue to benefit from zolpidem ER over six months with an acceptable (self-reported) side-effect profile. It does not prove that zolpidem ER is safe or effective for six months in the average new patient walking into a sleep clinic with comorbid depression, mild apnea, and a medicine cabinet of other prescriptions.

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

1. Krystal AD, Erman M, Zammit GK, et al. Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study. Sleep. 2010;33(11):1551-1561. https://pubmed.ncbi.nlm.nih.gov/18220081/
2. U.S. Food and Drug Administration. Ambien CR (zolpidem tartrate extended-release) prescribing information. Revised 2014. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021774s011lbl.pdf
3. FDA Drug Safety Communication: FDA requires lower recommended dose for certain sleep drugs containing zolpidem. January 2013. https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-lower-recommended-dose-certain-sleep-drugs-containing-zolpidem
4. Sateia MJ, Buysse DJ, Krystal AD, et al. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2017;13(2):307-349. https://pubmed.ncbi.nlm.nih.gov/28942757/
5. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003;326(7400):1167-1170. https://pubmed.ncbi.nlm.nih.gov/12775614/
6. NIH State-of-the-Science Conference Statement on Manifestations and Management of Chronic Insomnia in Adults. Sleep. 2005;28(9):1049-1057. https://pubmed.ncbi.nlm.nih.gov/16259539/